Review



si-ak7  (Keygen Biotech)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Keygen Biotech si-ak7
    Expression profile of <t>AK7</t> in tumor. ( A ) Expression of AK7 mRNA in different cancers and corresponding normal tissues. ( B ) The expression of AK7 mRNA in ccRCC was significantly higher than that in normal kidney tissue. ( C – G ) Differences in SPC25 mRNA expression depending on stage, grade, nodal metastasis status, subtype and race. ( H ) Expression of AK7 in normal renal tissues and ccRCC tissues. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Si Ak7, supplied by Keygen Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/si-ak7/product/Keygen Biotech
    Average 90 stars, based on 1 article reviews
    si-ak7 - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity"

    Article Title: AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity

    Journal: Aging (Albany NY)

    doi: 10.18632/aging.206006

    Expression profile of AK7 in tumor. ( A ) Expression of AK7 mRNA in different cancers and corresponding normal tissues. ( B ) The expression of AK7 mRNA in ccRCC was significantly higher than that in normal kidney tissue. ( C – G ) Differences in SPC25 mRNA expression depending on stage, grade, nodal metastasis status, subtype and race. ( H ) Expression of AK7 in normal renal tissues and ccRCC tissues. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Figure Legend Snippet: Expression profile of AK7 in tumor. ( A ) Expression of AK7 mRNA in different cancers and corresponding normal tissues. ( B ) The expression of AK7 mRNA in ccRCC was significantly higher than that in normal kidney tissue. ( C – G ) Differences in SPC25 mRNA expression depending on stage, grade, nodal metastasis status, subtype and race. ( H ) Expression of AK7 in normal renal tissues and ccRCC tissues. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Techniques Used: Expressing

    AK7 knockdown promoted the proliferation, invasion and migration ability of human ccRCC cell lines. ( A , B ) Three siRNAs (si1, si2, and si3) were designed to silence AK7 in ccRCC cells (786-O and Caki-1), and validated by qRT-PCR. ( C , D ) The growth curves of 786-O ( C ) and Caki-1 ( D ) cells were plotted after transfection with si1-AK7/si-NC based on CCK-8 assay. ( E , F ) Colony formation assays demonstrated that knockdown of AK7 promoted the proliferation of 786-O and Caki-1 cells. ( G – I ) Transwells experiment demonstrated that knockdown of AK7 expression could effectively promote the migration and invasion ability of ccRCC cells. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Figure Legend Snippet: AK7 knockdown promoted the proliferation, invasion and migration ability of human ccRCC cell lines. ( A , B ) Three siRNAs (si1, si2, and si3) were designed to silence AK7 in ccRCC cells (786-O and Caki-1), and validated by qRT-PCR. ( C , D ) The growth curves of 786-O ( C ) and Caki-1 ( D ) cells were plotted after transfection with si1-AK7/si-NC based on CCK-8 assay. ( E , F ) Colony formation assays demonstrated that knockdown of AK7 promoted the proliferation of 786-O and Caki-1 cells. ( G – I ) Transwells experiment demonstrated that knockdown of AK7 expression could effectively promote the migration and invasion ability of ccRCC cells. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Techniques Used: Knockdown, Migration, Quantitative RT-PCR, Transfection, CCK-8 Assay, Expressing

    Overexpression of AK7 inhibited proliferation, invasion and migration of human ccRCC cell lines. ( A , B ) qRT-PCR verified the efficiency of overexpression of AK7 in 786-O and AKI-1 cell lines. ( C , D ) The growth curves of 786-O ( C ) and Caki-1 ( D ) cells were plotted after overexpression of AK7 based on CCK-8 assay. ( E , F ) Colony formation assays demonstrated that overexpression of AK7 inhibited the proliferation of 786-O and Caki-1 cells. ( G – I ) Transwells experiment demonstrated that overexpression of AK7 could effectively inhibit the migration and invasion ability of ccRCC cells. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Figure Legend Snippet: Overexpression of AK7 inhibited proliferation, invasion and migration of human ccRCC cell lines. ( A , B ) qRT-PCR verified the efficiency of overexpression of AK7 in 786-O and AKI-1 cell lines. ( C , D ) The growth curves of 786-O ( C ) and Caki-1 ( D ) cells were plotted after overexpression of AK7 based on CCK-8 assay. ( E , F ) Colony formation assays demonstrated that overexpression of AK7 inhibited the proliferation of 786-O and Caki-1 cells. ( G – I ) Transwells experiment demonstrated that overexpression of AK7 could effectively inhibit the migration and invasion ability of ccRCC cells. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Techniques Used: Over Expression, Migration, Quantitative RT-PCR, CCK-8 Assay

    AK7 can be used as a prognostic indicator and a predictor of immunotherapy effect in ccRCC patients. ( A ) In pancarcinoma, patients with high expression of AK7 have a better prognosis than those with low expression. ( B ) In ccRCC, patients with high expression of AK7 had longer OS than those with low expression. ( C ) In ccRCC at stage 4, patients with high expression of AK7 had longer OS than those with low expression. ( D – F ) In patients treated with anti-PD1 ( D ), anti-PD-L1 ( E ), and anti-CTLA-4 ( F ), high expression of AK7 has a better prognosis. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Figure Legend Snippet: AK7 can be used as a prognostic indicator and a predictor of immunotherapy effect in ccRCC patients. ( A ) In pancarcinoma, patients with high expression of AK7 have a better prognosis than those with low expression. ( B ) In ccRCC, patients with high expression of AK7 had longer OS than those with low expression. ( C ) In ccRCC at stage 4, patients with high expression of AK7 had longer OS than those with low expression. ( D – F ) In patients treated with anti-PD1 ( D ), anti-PD-L1 ( E ), and anti-CTLA-4 ( F ), high expression of AK7 has a better prognosis. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Techniques Used: Expressing

    The expression of AK7 was correlated with immunosuppressive factors. ( A ) Correlation between AK7 and immunoinhibitors in different cancers. ( B ) The expression of AK7 was negatively correlated with the expression of CTLA4, TIGIT, IL10, PD1, IL0RB, LAG3 and other immunosuppressive factors. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Figure Legend Snippet: The expression of AK7 was correlated with immunosuppressive factors. ( A ) Correlation between AK7 and immunoinhibitors in different cancers. ( B ) The expression of AK7 was negatively correlated with the expression of CTLA4, TIGIT, IL10, PD1, IL0RB, LAG3 and other immunosuppressive factors. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Techniques Used: Expressing

    Overexpression of AK7 inhibits RCC growth and enhances anti-PD1 efficacy. ( A ) Schematic diagram of establishment of mouse subcutaneous tumor model in each group. ( B ) Three lentiviruses were designed to overexpress AK7 expression in RENCA cell lines, and their overexpression efficiency was verified by qRT-PCR. ( C ) Images of subcutaneous tumors in each group. ( D , E ) Analysis of subcutaneous tumors in the respective groups. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Figure Legend Snippet: Overexpression of AK7 inhibits RCC growth and enhances anti-PD1 efficacy. ( A ) Schematic diagram of establishment of mouse subcutaneous tumor model in each group. ( B ) Three lentiviruses were designed to overexpress AK7 expression in RENCA cell lines, and their overexpression efficiency was verified by qRT-PCR. ( C ) Images of subcutaneous tumors in each group. ( D , E ) Analysis of subcutaneous tumors in the respective groups. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Techniques Used: Over Expression, Expressing, Quantitative RT-PCR



    Similar Products

    si-ak7  (Keygen Biotech)
    90
    Keygen Biotech si-ak7
    Expression profile of <t>AK7</t> in tumor. ( A ) Expression of AK7 mRNA in different cancers and corresponding normal tissues. ( B ) The expression of AK7 mRNA in ccRCC was significantly higher than that in normal kidney tissue. ( C – G ) Differences in SPC25 mRNA expression depending on stage, grade, nodal metastasis status, subtype and race. ( H ) Expression of AK7 in normal renal tissues and ccRCC tissues. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
    Si Ak7, supplied by Keygen Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/si-ak7/product/Keygen Biotech
    Average 90 stars, based on 1 article reviews
    si-ak7 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Expression profile of AK7 in tumor. ( A ) Expression of AK7 mRNA in different cancers and corresponding normal tissues. ( B ) The expression of AK7 mRNA in ccRCC was significantly higher than that in normal kidney tissue. ( C – G ) Differences in SPC25 mRNA expression depending on stage, grade, nodal metastasis status, subtype and race. ( H ) Expression of AK7 in normal renal tissues and ccRCC tissues. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Journal: Aging (Albany NY)

    Article Title: AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity

    doi: 10.18632/aging.206006

    Figure Lengend Snippet: Expression profile of AK7 in tumor. ( A ) Expression of AK7 mRNA in different cancers and corresponding normal tissues. ( B ) The expression of AK7 mRNA in ccRCC was significantly higher than that in normal kidney tissue. ( C – G ) Differences in SPC25 mRNA expression depending on stage, grade, nodal metastasis status, subtype and race. ( H ) Expression of AK7 in normal renal tissues and ccRCC tissues. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Article Snippet: Cells were cultured in a 5% CO 2 chamber at 37°C with RFMI-1640 (Gibco, USA) containing 10% FBS (NEWZERUM, Newzerum, Christchurch, New Zealand) and 1% P-S. si-AK7 and si-NC were produced by KeyGEN BioTECH (Jiangsu, China).

    Techniques: Expressing

    AK7 knockdown promoted the proliferation, invasion and migration ability of human ccRCC cell lines. ( A , B ) Three siRNAs (si1, si2, and si3) were designed to silence AK7 in ccRCC cells (786-O and Caki-1), and validated by qRT-PCR. ( C , D ) The growth curves of 786-O ( C ) and Caki-1 ( D ) cells were plotted after transfection with si1-AK7/si-NC based on CCK-8 assay. ( E , F ) Colony formation assays demonstrated that knockdown of AK7 promoted the proliferation of 786-O and Caki-1 cells. ( G – I ) Transwells experiment demonstrated that knockdown of AK7 expression could effectively promote the migration and invasion ability of ccRCC cells. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Journal: Aging (Albany NY)

    Article Title: AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity

    doi: 10.18632/aging.206006

    Figure Lengend Snippet: AK7 knockdown promoted the proliferation, invasion and migration ability of human ccRCC cell lines. ( A , B ) Three siRNAs (si1, si2, and si3) were designed to silence AK7 in ccRCC cells (786-O and Caki-1), and validated by qRT-PCR. ( C , D ) The growth curves of 786-O ( C ) and Caki-1 ( D ) cells were plotted after transfection with si1-AK7/si-NC based on CCK-8 assay. ( E , F ) Colony formation assays demonstrated that knockdown of AK7 promoted the proliferation of 786-O and Caki-1 cells. ( G – I ) Transwells experiment demonstrated that knockdown of AK7 expression could effectively promote the migration and invasion ability of ccRCC cells. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Article Snippet: Cells were cultured in a 5% CO 2 chamber at 37°C with RFMI-1640 (Gibco, USA) containing 10% FBS (NEWZERUM, Newzerum, Christchurch, New Zealand) and 1% P-S. si-AK7 and si-NC were produced by KeyGEN BioTECH (Jiangsu, China).

    Techniques: Knockdown, Migration, Quantitative RT-PCR, Transfection, CCK-8 Assay, Expressing

    Overexpression of AK7 inhibited proliferation, invasion and migration of human ccRCC cell lines. ( A , B ) qRT-PCR verified the efficiency of overexpression of AK7 in 786-O and AKI-1 cell lines. ( C , D ) The growth curves of 786-O ( C ) and Caki-1 ( D ) cells were plotted after overexpression of AK7 based on CCK-8 assay. ( E , F ) Colony formation assays demonstrated that overexpression of AK7 inhibited the proliferation of 786-O and Caki-1 cells. ( G – I ) Transwells experiment demonstrated that overexpression of AK7 could effectively inhibit the migration and invasion ability of ccRCC cells. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Journal: Aging (Albany NY)

    Article Title: AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity

    doi: 10.18632/aging.206006

    Figure Lengend Snippet: Overexpression of AK7 inhibited proliferation, invasion and migration of human ccRCC cell lines. ( A , B ) qRT-PCR verified the efficiency of overexpression of AK7 in 786-O and AKI-1 cell lines. ( C , D ) The growth curves of 786-O ( C ) and Caki-1 ( D ) cells were plotted after overexpression of AK7 based on CCK-8 assay. ( E , F ) Colony formation assays demonstrated that overexpression of AK7 inhibited the proliferation of 786-O and Caki-1 cells. ( G – I ) Transwells experiment demonstrated that overexpression of AK7 could effectively inhibit the migration and invasion ability of ccRCC cells. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Article Snippet: Cells were cultured in a 5% CO 2 chamber at 37°C with RFMI-1640 (Gibco, USA) containing 10% FBS (NEWZERUM, Newzerum, Christchurch, New Zealand) and 1% P-S. si-AK7 and si-NC were produced by KeyGEN BioTECH (Jiangsu, China).

    Techniques: Over Expression, Migration, Quantitative RT-PCR, CCK-8 Assay

    AK7 can be used as a prognostic indicator and a predictor of immunotherapy effect in ccRCC patients. ( A ) In pancarcinoma, patients with high expression of AK7 have a better prognosis than those with low expression. ( B ) In ccRCC, patients with high expression of AK7 had longer OS than those with low expression. ( C ) In ccRCC at stage 4, patients with high expression of AK7 had longer OS than those with low expression. ( D – F ) In patients treated with anti-PD1 ( D ), anti-PD-L1 ( E ), and anti-CTLA-4 ( F ), high expression of AK7 has a better prognosis. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Journal: Aging (Albany NY)

    Article Title: AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity

    doi: 10.18632/aging.206006

    Figure Lengend Snippet: AK7 can be used as a prognostic indicator and a predictor of immunotherapy effect in ccRCC patients. ( A ) In pancarcinoma, patients with high expression of AK7 have a better prognosis than those with low expression. ( B ) In ccRCC, patients with high expression of AK7 had longer OS than those with low expression. ( C ) In ccRCC at stage 4, patients with high expression of AK7 had longer OS than those with low expression. ( D – F ) In patients treated with anti-PD1 ( D ), anti-PD-L1 ( E ), and anti-CTLA-4 ( F ), high expression of AK7 has a better prognosis. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Article Snippet: Cells were cultured in a 5% CO 2 chamber at 37°C with RFMI-1640 (Gibco, USA) containing 10% FBS (NEWZERUM, Newzerum, Christchurch, New Zealand) and 1% P-S. si-AK7 and si-NC were produced by KeyGEN BioTECH (Jiangsu, China).

    Techniques: Expressing

    The expression of AK7 was correlated with immunosuppressive factors. ( A ) Correlation between AK7 and immunoinhibitors in different cancers. ( B ) The expression of AK7 was negatively correlated with the expression of CTLA4, TIGIT, IL10, PD1, IL0RB, LAG3 and other immunosuppressive factors. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Journal: Aging (Albany NY)

    Article Title: AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity

    doi: 10.18632/aging.206006

    Figure Lengend Snippet: The expression of AK7 was correlated with immunosuppressive factors. ( A ) Correlation between AK7 and immunoinhibitors in different cancers. ( B ) The expression of AK7 was negatively correlated with the expression of CTLA4, TIGIT, IL10, PD1, IL0RB, LAG3 and other immunosuppressive factors. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Article Snippet: Cells were cultured in a 5% CO 2 chamber at 37°C with RFMI-1640 (Gibco, USA) containing 10% FBS (NEWZERUM, Newzerum, Christchurch, New Zealand) and 1% P-S. si-AK7 and si-NC were produced by KeyGEN BioTECH (Jiangsu, China).

    Techniques: Expressing

    Overexpression of AK7 inhibits RCC growth and enhances anti-PD1 efficacy. ( A ) Schematic diagram of establishment of mouse subcutaneous tumor model in each group. ( B ) Three lentiviruses were designed to overexpress AK7 expression in RENCA cell lines, and their overexpression efficiency was verified by qRT-PCR. ( C ) Images of subcutaneous tumors in each group. ( D , E ) Analysis of subcutaneous tumors in the respective groups. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Journal: Aging (Albany NY)

    Article Title: AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity

    doi: 10.18632/aging.206006

    Figure Lengend Snippet: Overexpression of AK7 inhibits RCC growth and enhances anti-PD1 efficacy. ( A ) Schematic diagram of establishment of mouse subcutaneous tumor model in each group. ( B ) Three lentiviruses were designed to overexpress AK7 expression in RENCA cell lines, and their overexpression efficiency was verified by qRT-PCR. ( C ) Images of subcutaneous tumors in each group. ( D , E ) Analysis of subcutaneous tumors in the respective groups. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.

    Article Snippet: Cells were cultured in a 5% CO 2 chamber at 37°C with RFMI-1640 (Gibco, USA) containing 10% FBS (NEWZERUM, Newzerum, Christchurch, New Zealand) and 1% P-S. si-AK7 and si-NC were produced by KeyGEN BioTECH (Jiangsu, China).

    Techniques: Over Expression, Expressing, Quantitative RT-PCR